Innate mechanisms of viral recognition

Molecular Biology

Volumn 45, Issue 1, 2011, Pages 5-15

  Drutskaya, M S ^a   Belousov, P V ^b   Nedospasov, S A ^a,b  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

antiviral response; innate immunity; pathogen recognition receptors; RIG l like receptors; toll like receptors

Indexed keywords

HEXAPODA; INVERTEBRATA; MAMMALIA; VERTEBRATA;

EID: 79951991957     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893311010043     Document Type: Review

References (87)

1. Hoffmann J. A. 2003. The immune response of Drosophila. Nature. 426, 33-38.
2. Caplan J., Padmanabhan M., Dinesh-Kumar S. P. 2008. Plant NB-LRR immune receptors: From recognition to transcriptional reprogramming. Cell Host Microbe. 3, 126-135.
3. Deddouche S., Matt N., Budd A., Mueller S., Kemp C., Galiana-Arnoux D., Dostert C., Antoniewski C., Hoffmann J. A., Imler J. L. 2008. The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in drosophila. Nature Immunol. 9, 1425-1432.
4. Aliyari R., Ding S. W. 2009. RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol. Rev. 227, 176-188.
5. Saleh M. C., Tassetto M., van Rij R. P., Goic B., Gausson V., Berry B., Jacquier C., Antoniewski C., Andino R. 2009. Antiviral immunity in Drosophila requires systemic RNA interference spread. Nature. 458, 346-350.
6. Pancer Z., Amemiya C. T., Ehrhardt G. R., Ceitlin J., Gartland G. L., Cooper M. D. 2004. Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature. 430, 174-180.
7. Kawai T., Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol. 11, 373-384.
8. Iwasaki A., Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science. 327, 291-295.
9. Kawai T., Akira S. 2006. Innate immune recognition of viral infection. Nature Immunol. 7, 131-137.
10. Ting J. P., Duncan J. A., Lei Y. 2010. How the noninflammasome NLRs function in the innate immune system. Science. 327, 286-290.
11. Moore C. B., Bergstralh D. T., Duncan J. A., Lei Y., Morrison T. E., Zimmermann A. G., Accavitti-Loper M. A., Madden V. J., Sun L., Ye Z., Lich J. D., Heise M. T., Chen Z., Ting J. P. 2008. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature. 451, 573-577.
12. Ewald S. E., Lee B. L., Lau L., Wickliffe K. E., Shi G. P., Chapman H. A., Barton G. M. 2008. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 456, 658-662.
13. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303, 1526-1529.
14. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., Akira S. 2002. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169, 6668-6672.
15. Oshiumi H., Matsumoto M., Funami K., Akazawa T., Seya T. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nature Immunol. 4, 161-167.
16. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., Akira S. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301, 640-643.
17. Sharma S., tenOever B. R., Grandvaux N., Zhou G. P., Lin R., Hiscott J. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science. 300, 1148-1151.
18. Fitzgerald K. A., McWhirter S. M., Faia K. L., Rowe D. C., Latz E., Golenbock D. T., Coyle A. J., Liao S. M., Maniatis T. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunol. 4, 491-496.
19. Hemmi H., Kaisho T., Takeda K., Akira S. 2003. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170, 3059-3064.
20. Hoshino K., Kaisho T., Iwabe T., Takeuchi O., Akira S. 2002. Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14, 1225-1231.
21. Uematsu S., Sato S., Yamamoto M., Hirotani T., Kato H., Takeshita F., Matsuda M., Coban C., Ishii K. J., Kawai T., Takeuchi O., Akira S. 2005. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction. J. Exp. Med. 201, 915-923.
22. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. 2004. The RNA helicase RIG-1 has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737.
23. Andrejeva J., Childs K. S., Young D. F., Carlos T. S., Stock N., Goodbourn S., Randall R. E. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA. 101, 17264-17269.
24. Hemmi H., Takeuchi O., Sato S., Yamamoto M., Kaisho T., Sanjo H., Kawai T., Hoshino K., Takeda K., Akira S. 2004. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199, 1641-1650.
25. Perry A. K., Chow E. K., Goodnough J. B., Yeh W. C., Cheng G. 2004. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J. Exp. Med. 199, 1651-1658.
26. Pichlmair A., Reis e Sousa C. 2007. Innate recognition of viruses. Immunity. 27, 370-383.
27. Poeck H., Bscheider M., Gross O., Finger K., Roth S., Rebsamen M., Hannesschlager N., Schlee M., Rothenfusser S., Barchet W., Kato H., Akira S., Inoue S., Endres S., Peschel C., Hartmann G., Hornung V., Ruland J. 2010. Recognition of RNA virus by RIG-1 results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nature Immunol. 11, 63-69.
28. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K. J., Yamaguchi O., Otsu K., Tsujimura T., Koh C. S., Reis e Sousa C., Matsuura Y., Fujita T., Akira S. 2006. Differential roles of MDA5 and RIG-1 helicases in the recognition of RNA viruses. Nature. 441, 101-105.
29. Loo Y. M., Fornek J., Crochet N., Bajwa G., Perwitasari O., Martinez-Sobrido L., Akira S., Gill M. A., Garcia-Sastre A., Katze M. G., Gale M., Jr. 2008. Distinct RIG-1 and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82, 335-345.
30. Satoh T., Kato H., Kumagai Y., Yoneyama M., Sato S., Matsushita K., Tsujimura T., Fujita T., Akira S., Takeuchi O. 2010. LGP2 is a positive regulator of RIG-1- and MDA5-mediated antiviral responses. Proc. Natl. Acad. Sci. USA. 107, 1512-1517.
31. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K. K., Schlee M., Endres S., Hartmann G. 2006. 5′-Triphosphate RNA is the ligand for RIG-1. Science. 314, 994-997.
32. Pichlmair A., Schulz O., Tan C. P., Rehwinkel J., Kato H., Takeuchi O., Akira S., Way M., Schiavo G., Reis e Sousa C. 2009. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 83, 10761-10769.
33. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., Gale M., Jr., Inagaki F., Fujita T. 2008. Nonself RNA-sensing mechanism of RIG-1 helicase and activation of antiviral immune responses. Mol. Cell. 29, 428-440.
34. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T. S., Fujita T., Akira S. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205, 1601-1610.
35. Malathi K., Dong B., Gale M., Jr., Silverman R. H. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature. 448, 816-819.
36. Rehwinkel J., Tan C. P., Goubau D., Schulz O., Pichlmair A., Bier K., Robb N., Vreede F., Barclay W., Fodor E., Reis e Sousa C. 2010. RIG-1 detects viral genomic RNA during negative-strand RNA virus infection. Cell. 140, 397-408.
37. Rehwinkel J., Reis e Sousa C. 2010. RIGorous detection: Exposing virus through RNA sensing. Science. 327, 284-286.
38. Chiu Y. H., Macmillan J. B., Chen Z. J. 2009. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-1 pathway. Cell. 138, 576-591.
39. Ablasser A., Bauernfeind F., Hartmann G., Latz E., Fitzgerald K. A., Hornung V. 2009. RIG-1-dependent sensing of poly(dA: dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nature Immunol. 10, 1065-1072.
40. Burckstummer T., Baumann C., Bluml S., Dixit E., Durnberger G., Jahn H., Planyavsky M., Bilban M., Colinge J., Bennett K. L., Superti-Furga G. 2009. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nature Immunol. 10, 266-272.
41. Fernandes-Alnemri T., Yu J. W., Datta P., Wu J., Alnemri E. S. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 458, 509-513.
42. Roberts T. L., Idris A., Dunn J. A., Kelly G. M., Burnton C. M., Hodgson S., Hardy L. L., Garceau V., Sweet M. J., Ross I. L., Hume D. A., Stacey K. J. 2009. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 323, 1057-1060.
43. Takaoka A., Wang Z., Choi M. K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., Taniguchi T. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 448, 501-505.
44. Xu L. G., Wang Y. Y., Han K. J., Li L. Y., Zhai Z., Shu H. B. 2005. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell. 19, 727-740.
45. Seth R. B., Sun L., Ea C. K., Chen Z. J. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 122, 669-682.
46. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K. J., Takeuchi O., Akira S. 2005. IPS-1, an adaptor triggering RIG-1- and Mda5-mediated type I interferon induction. Nature Immunol. 6, 981-988.
47. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. 2005. Cardif is an adaptor protein in the RIG-1 antiviral pathway and is targeted by hepatitis C virus. Nature. 437, 1167-1172.
48. Sabbah A., Chang T. H., Harnack R., Frohlich V., Tominaga K., Dube P. H., Xiang Y., Bose S. 2009. Activation of innate immune antiviral responses by Nod2. Nature Immunol. 10, 1073-1080.
49. Dugan J. W., Albor A., David L., Fowlkes J., Blackledge M. T., Martin T. M., Planck S. R., Rosenzweig H. L., Rosenbaum J. T., Davey M. P. 2009. Nucleotide oligomerization domain-2 interacts with 2′-5′-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Mol. Immunol. 47, 560-566.
50. Onoguchi K., Yoneyama M., Takemura A., Akira S., Taniguchi T., Namiki H., Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 282, 7576-7581.
51. Haller O., Kochs G., Weber F. 2007. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev. 18, 425-433.
52. Malmgaard L. 2004. Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 24, 439-454.
53. Samuel C. E. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809.
54. Honda K., Takaoka A., Taniguchi T. 2006. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity. 25, 349-360.
55. Lanier L. L. 2008. Evolutionary struggles between NK cells and viruses. Nature Rev. Immunol. 8, 259-268.
56. Ahlenstiel G., Martin M. P., Gao X., Carrington M., Rehermann B. 2008. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J. Clin. Invest. 118, 1017-1026.
57. Fehniger T. A., Cai S. F., Cao X., Bredemeyer A. J., Presti R. M., French A. R., Ley T. J. 2007. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 26, 798-811.
58. Sivori S. 2004. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA. 101, 10116-10121.
59. Schmidt K. N. 2004. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 172, 138-143.
60. Zhang S. Y. 2007. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 317, 1522-1527.
61. Hansen S. G., Powers C. J., Richards R., Ventura A. B., Ford J. C., Siess D., Axthelm M. K., Nelson J. A., Jarvis M. A., Picker L. J., Fruh K. 2010. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 328, 102-106.
62. Pinto A. K., Hill A. B. 2005. Viral interference with antigen presentation to CD8+ T cells: Lessons from cytomegalovirus. Viral Immunol. 18, 434-444.
63. Muller S., Zocher G., Steinle A., Stehle T. 2010. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. PLoS Pathog. 6, e1000723.
64. Ashiru O., Bennett N. J., Boyle L. H., Thomas M., Trowsdale J., Wills M. R. 2009. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J. Virol. 83, 12345-12354.
65. Tomasec P., Wang E. C., Davison A. J., Vojtesek B., Armstrong M., Griffin C., McSharry B. P., Morris R. J., Llewellyn-Lacey S., Rickards C., Nomoto A., Sinzger C., Wilkinson G. W. 2005. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nature Immunol. 6, 181-188.
66. Prod'homme V., Sugrue D. M., Stanton R. J., Nomoto A., Davies J., Rickards C. R., Cochrane D., Moore M., Wilkinson G. W., Tomasec P. 2010. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J. Gen. Virol. 91, 2034-2039.
67. Stern-Ginossar N., Elefant N., Zimmermann A., Wolf D. G., Saleh N., Biton M., Horwitz E., Prokocimer Z., Prichard M., Hahn G., Goldman-Wohl D., Greenfield C., Yagel S., Hengel H., Altuvia Y., Margalit H., Mandelboim O. 2007. Host immune system gene targeting by a viral miRNA. Science. 317, 376-381.
68. Cheng G., Zhong J., Chisari F. V. 2006. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA. 103, 8499-8504.
69. Sumpter R., Jr., Loo Y. M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S. M., Gale M., Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-1. J. Virol. 79, 2689-2699.
70. Foy E., Li K., Sumpter R., Jr., Loo Y. M., Johnson C. L., Wang C., Fish P. M., Yoneyama M., Fujita T., Lemon S. M., Gale M., Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA. 102, 2986-2991.
71. Arnaud N., Dabo S., Maillard P., Budkowska A., Kalliampakou K. I., Mavromara P., Garcin D., Hugon J., Gatignol A., Akazawa D., Wakita T., Meurs E. F. 2010. Hepatitis C virus controls interferon production through PKR activation. PLoS One. 5, e10575.
72. Ferreon J. C., Ferreon A. C., Li K., Lemon S. M. 2005. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J. Biol. Chem. 280, 20483-20492.
73. Li K., Foy E., Ferreon J. C., Nakamura M., Ferreon A. C., Ikeda M., Ray S. C., Gale M., Jr., Lemon S. M. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA. 102, 2992-2997.
74. Stack J., Haga I. R., Schroder M., Bartlett N. W., Maloney G., Reading P. C., Fitzgerald K. A., Smith G. L., Bowie A. G. 2005. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201, 1007-1018.
75. Garcia-Sastre A., Biron C. A. 2006. Type 1 interferons and the virus-host relationship: A lesson in detente. Science. 312, 879-882.
76. Symons J. A., Alcami A., Smith G. L. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 81, 551-560.
77. Nishio M., Tsurudome M., Ito M., Garcin D., Kolakofsky D., Ito Y. 2005. Identification of paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J. Virol. 79, 8591-8601.
78. Rodriguez J. J., Cruz C. D., Horvath C. M. 2004. Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. J. Virol. 78, 5358-5367.
79. Shaw M. L., Garcia-Sastre A., Palese P., Basler C. F. 2004. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J. Virol. 78, 5633-5641.
80. Frey K. G., Ahmed C. M., Dabelic R., Jager L. D., Noon-Song E. N., Haider S. M., Johnson H. M., Bigley N. J. 2009. HSV-1-induced SOCS-1 expression in keratinocytes: Use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion. J. Immunol. 183, 1253-1262.
81. Gainey M. D., Dillon P. J., Clark K. M., Manuse M. J., Parks G. D. 2008. Paramyxovirus-induced shutoff of host and viral protein synthesis: Role of the P and V proteins in limiting PKR activation. J. Virol. 82, 828-839.
82. Toroney R., Nallagatla S. R., Boyer J. A., Cameron C. E., Bevilacqua P. C. 2010. Regulation of PKR by HCV IRES RNA: Importance of domain II and NS5A. J. Mol. Biol. 400, 393-412.
83. Schumann M., Gantke T., Muhlberger E. 2009. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 8993-8997.
84. Myskiw C., Arsenio J., van Bruggen R., Deschambault Y., Cao J. 2009. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J. Virol. 83, 6757-6768.
85. Shchelkunov S. N., Blinov V. M., Sandakhchiev L. S. 1993. Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms. FEBS Lett. 319, 80-83.
86. Shchelkunov S. N., Resenchuk S. M., Totmenin A. V., Kolykhalov A. A., Frolov I. V., Dryga S. M., Volchkov V. V., Chizhikov V. E., Gutorov V. V., Blinov V. M., Sandakhchiev L. S. 1994. Structure-activity organization of the variola virus genome: 3. Sequencing and analysis of the nucleotide sequence of the conserved region of HindIII-F, -N, and -A fragments of the India 1967 strain genome. Mol. Biol. (Moscow). 28, 265-273.
87. Shchelkunov S. N., Blinov V. M., Resenchuk S. M., Gutorov V. V., Safronov P. F., Kurmanov R. K., Totmenin A. V., Chizhikov V. E., Marennikova S. S., Sandakhchiev L. S. 1993. Study of the structure-activity organization of the variola virus genome: 2. Analysis of the nucleotide sequence of the HindIII region (C, E, R, Q, K, and H) DNA fragments of the India-1967 strain. Mol. Biol. (Moscow). 27, 797-811.